恩度联合紫杉醇和卡铂靶向治疗晚期非小细胞肺癌效果观察

Endostar Combined with Paclitaxel and Carboplatin in Targeted Treatment of Advanced Non- small Cell Lung Cancer:An Observation of Clinical Effect

目的探讨恩度(重组人血管内皮抑制素)联合紫杉醇和卡铂靶向治疗晚期NSCLC患者的早期临床效果。方法 69例住院的晚期NSCLC患者随机分为观察组38例、对照组31例,疗程结束后按WHO恶性肿瘤疗效评定标准判定疗效。结果观察组患者胸部CT的瘤体中位直径治疗前较治疗后缩小了(2.74±0.24)cm,而对照组仅缩小(2.09±0.42)cm(P<0.05);观察组PR21例,SD14例,有效率为92.11%,对照组PR11例,SD7例,有效率为58.06%,观察组有效率显著高于对照组(P<0.01)。结论应用恩度联合紫杉醇和卡铂靶向治疗晚期NSCLC早期临床观察瘤体缩小明显,有效率和临床受益率明显高于对照组。

Objective To study the early clinical effect of Endostar （recombinant human endostatin） combined with paclitaxel and carboplatin in the targeted treatment of advanced non-small cell lung cancer（NSCLC ）. Methods Sixty-nine cases of advanced NSCLC treated by Endostar combined with paclitaxel and carboplatin were divided into two groups： observation group（38 cases） and control group （3 l cases）, After treatment,all the cases were assessed by using WHO standards for the efficacy of malignant tumors. Results In the observation group, the median diameter was reduced by （2.74 ± 0.24）cm. And in the control group, it was reduced by （2.09 ± 0.42）cm. The observation group showed 21 cases of PR and 14 cases of SD,with the effective rate of 92.11%. The control group showed 11 cases of PR and 7 cases of SD, with the effective rate of 58.06%. Conclusion Endostar combined with paclitaxel and carboplatin can reduce tumor size significantly in the targeted treatment of advanced（ NSCLC, with significantly higher efficiency and clinical benefit rates）.